Advances in Our Understanding of ALK-Related Cancers: A Selection of Papers from the Joint Annual Meeting of the European Research Initiative for ALK-Related Malignancies (ERIA) and the European Union Marie Curie European Training Network ALKATRAS

A special issue of Cancers (ISSN 2072-6694).

Deadline for manuscript submissions: closed (15 November 2017) | Viewed by 78850

Special Issue Editors

Division of Cellular and Molecular Pathology, Department of Pathology, University of Cambridge, Lab Block Level 3, Box 231, Addenbrooke’s Hospital, Cambridge CB20QQ, UK
Department of Experimental Pathology and Laboratory Animal Pathology, Medical University Vienna, 1090 Vienna, Austria
Interests: laboratory animal pathology; molecular pathology; prostate cancer; ALCL
Dr. Olaf Merkel
E-Mail Website
Guest Editor
Institute of Clinical Pathology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria
Interests: childhood Lymphoma; tyrosine kinase; genomic aberrations; super-enhancer; transcription factors; miRNA; non-coding RNA; drug screening; structure/function guided drug development; anaplastic large cell lymphoma

Special Issue Information

Dear Colleagues,

This Special Issue of Cancers will consist of selected papers from the “Joint 8th Annual Meeting of the European Research Initiative for ALK Related Malignancies (ERIA) and the 2nd Annual meeting of the European Union Marie Curie European Training network, ALK as a target of translational science (ALKATRAS) ( and”, taking place in Cambridge (UK), on 28–29 September 2017. ERIA was established in 2009 to bring together scientists and clinicians with a shared interest in ALK-related cancers and to provide a platform for the exchange of scientific data, reagents and informal peer review. Largely, this is mediated through annual meetings and whilst originally solely a European enterprise, now incorporates research groups from across the World. In 2016, 14 research groups, all members of ERIA were awarded an EU Marie Curie European training Network, ALKATRAS which has enabled further collaboration through a network of 15 PhD students recruited from around the world and representing the next generation of ERIA members. As such, this international conference represents the major event for the scientific community working on ALK-related cancers and promises to be an exciting and exhilarating meeting. Particular attention is given to trainees, whereby students are encouraged to present their early, unpublished data to facilitate collaboration and advancement in this important area of research. This Special Issue will cover new and novel areas of research pertaining to ALK-related malignancies presented at this conference and therefore will represent state-of-the-art and up-to-date coverage of progress.

Dr. Suzanne Turner
Prof. Lukas Kenner
Dr. Olaf Merkel
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (9 papers)

Order results
Result details
Select all
Export citation of selected articles as:
23 pages, 1001 KiB  
The Transcriptional Roles of ALK Fusion Proteins in Tumorigenesis
Cancers 2019, 11(8), 1074; - 30 Jul 2019
17 pages, 268 KiB  
Current Immunotherapeutic Approaches in T Cell Non-Hodgkin Lymphomas
Cancers 2018, 10(9), 339; - 18 Sep 2018
13 pages, 4646 KiB  
Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma
Cancers 2018, 10(4), 114; - 10 Apr 2018
16 pages, 3999 KiB  
ALK in Neuroblastoma: Biological and Therapeutic Implications
Cancers 2018, 10(4), 113; - 10 Apr 2018
22 pages, 88948 KiB  
The Pathological Spectrum of Systemic Anaplastic Large Cell Lymphoma (ALCL)
Cancers 2018, 10(4), 107; - 04 Apr 2018
18 pages, 543 KiB  
Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond
Cancers 2018, 10(4), 99; - 30 Mar 2018
22 pages, 5147 KiB  
The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas
Cancers 2018, 10(4), 93; - 28 Mar 2018
12 pages, 1765 KiB  
The Role of Oncogenic Tyrosine Kinase NPM-ALK in Genomic Instability
Cancers 2018, 10(3), 64; - 05 Mar 2018
30 pages, 1702 KiB  
Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes
Cancers 2018, 10(3), 62; - 28 Feb 2018
Back to TopTop